SAWAI GROUP HOLDINGS Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

The first quarter saw higher revenue but lower earnings, with cost increases and inventory accumulation affecting profitability and cash flow as the key points. Revenue increased to ¥516.2B (+4.3% YoY), but Operating Income declined significantly to ¥49.5B (-29.0%) and Net Income to ¥24.3B (-50.3%). In addition to the decline in gross margin (29.2%, approximately -100bp YoY), increases in selling, general and administrative expenses (+16.4%) and research and development expenses (+22.9%) exceeded revenue growth, causing negative operating leverage and representing the primary factors behind the decline.

Factors Affecting Performance

【Revenue】Revenue was ¥516.2B (+4.3% YoY). By therapeutic category, cardiovascular drugs, other metabolic drugs, and central nervous system drugs contributed to revenue growth, while antibiotic preparations (2,535→2,088 million yen) and respiratory drugs (1,925→1,457 million yen) declined. The main contributor to revenue growth was other metabolic drugs (+1,938 million yen), with changes in the product mix reflected in the revenue composition.

【Profit and Loss】Operating Income was ¥49.5B (-29.0% YoY), Profit Before Tax was ¥44.5B (-34.7%), and Net Income was ¥24.3B (-50.3%). Cost of sales increased by +7.2%, deteriorating the gross margin, while increases in selling, general and administrative expenses and research and development expenses pressured earnings. Finance costs also increased to ¥5.6B (¥3.1B in the previous year), weighing on Profit Before Tax. In addition, a loss of ¥4.3B from discontinued operations further reduced Net Income. Overall, the Company posted higher revenue but lower earnings.

Segment Analysis

The business consists of a single segment, “Manufacturing and sales of pharmaceuticals and related products,” and operating income and loss by business are not disclosed. By therapeutic category, revenue from cardiovascular drugs increased to ¥117.1B (¥115.5B in the previous year), other metabolic drugs to ¥77.3B (¥57.9B in the previous year, +33.5%), and central nervous system drugs to ¥74.5B (¥69.9B in the previous year). Meanwhile, antibiotic preparations (-17.6%) and respiratory drugs (-24.3%) declined, resulting in a composition in which growth and contraction areas coexist.

Key Financial Indicators

【Profitability】The Operating Income margin was 9.6%, down from approximately 13.1% in the previous year, while the Net Income margin also contracted significantly to 4.7% from approximately 9.9% in the previous year. The gross margin was 29.2%, down from the previous year.【Cash Flow Quality】Operating Cash Flow (OCF) was -¥4.3B, below Net Income of ¥24.3B, resulting in a negative OCF/Net Income ratio. The primary factor was a ¥79.7B quarterly increase in inventories, indicating a lengthening inventory turnover period.【Investment Efficiency】ROE was 1.4%; as Net Income contracted while assets expanded, capital efficiency remained low.【Financial Soundness】The Equity Ratio declined slightly to 48.1% (49.6% in the previous year) but remained at a conservative level. Short-term borrowings rose sharply to ¥398.2B (¥146.8B in the previous year), indicating that investment and inventory funding is being supplemented through short-term financing.

Cash Flow Analysis

Operating Cash Flow (OCF) was -¥4.3B, an improvement from -¥134.1B in the previous year, but cash conversion has not progressed relative to Net Income of ¥24.3B. The primary factor was the ¥79.7B increase in inventories, with deterioration in working capital offsetting cash generation from operating activities. Investing Cash Flow was -¥127.1B, of which ¥105.8B comprised capital expenditures, indicating a more aggressive investment stance than in the previous year (-¥24.0B). As a result, Free Cash Flow was -¥131.3B, with funding requirements covered by Financing Cash Flow of +¥102.0B, particularly a net increase in short-term borrowings of ¥156.5B. Cash and cash equivalents declined to ¥260.6B, highlighting an increasing dependence on short-term debt in the funding structure.

Earnings Quality

Current-period Net Income of ¥24.3B includes a ¥4.3B loss from discontinued operations, which can be distinguished as a temporary factor. Profit from continuing operations alone was ¥28.6B, and the decline in earnings would be somewhat smaller on this basis. Finance costs increased to ¥5.6B, with non-operating costs weighing on Profit Before Tax. Comprehensive income was ¥23.2B, remaining approximately at the same level as Net Income of ¥24.3B; the divergence attributable to other comprehensive income (a -¥1.1B change in financial assets measured at fair value) was limited. Meanwhile, the fact that OCF was below Net Income warrants attention from an accrual perspective, as the gap between accounting earnings and cash generation resulting from inventory accumulation is a key issue in assessing earnings quality.

Earnings Forecast and Guidance

Against the full-year Company plan, Revenue was ¥208.4B compared with ¥516.2B in the current quarter, representing progress of 24.8% and generally consistent with seasonality (Q1 benchmark: 25%). Meanwhile, Operating Income was 18.2% of the full-year target of ¥272.0B, and Net Income was 13.1% of the full-year target of ¥186.0B (attributable to owners of the parent), indicating that earnings progress is lagging revenue progress in both cases. The full-year plan forecasts growth of +71.1% in Operating Income and +78.2% in Net Income, and appears to incorporate an assumption that the Q1 deterioration in gross margin and increase in expenses will recover toward the second half of the fiscal year. No revisions to the earnings forecast had been made as of the current quarter.

Shareholder Returns

Dividend payments during the current quarter were ¥32.3B (¥31.2B in the previous year), and the full-year forecast dividend per share is 56 yen. Using the full-year forecast Net Income of ¥186.0B (attributable to owners of the parent) as the denominator, the Payout Ratio calculated from the estimated total dividend amount (approximately 115.5 million issued shares × 56 yen = approximately ¥64.7B) is approximately 34.8%. Free Cash Flow for the current quarter was negative at -¥131.3B, confirming that dividends are currently being supported not by cash generated from operating activities but by borrowings and other financing sources.

Risk Factors

1. Working capital risk associated with inventory accumulation: Inventories increased to ¥1,255.8B (¥1,176.1B at the end of the previous fiscal year, +¥79.7B), putting pressure on OCF. If elevated inventory levels persist, the impact on cash-generation capacity may continue over the longer term.

2. Refinancing risk arising from dependence on short-term funding: Short-term borrowings increased sharply to ¥398.2B (+171.4% from ¥146.8B at the end of the previous fiscal year). The ratio to cash and cash equivalents of ¥260.6B was approximately 0.65x, indicating an increased dependence on short-term debt.

3. Declining profitability: The Operating Income margin was 9.6% (down from approximately 13.1% in the previous year), and the Net Income margin was 4.7% (down from approximately 9.9% in the previous year). Growth in selling, general and administrative expenses and research and development expenses (+16.4% and +22.9%, respectively) exceeded revenue growth (+4.3%), making the absorption of cost increases a key challenge.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

The Company’s profitability metrics are below the industry median, with its Operating Income margin particularly ranking in the lower tier of the industry.

Growth and Capital Efficiency

Revenue growth also fell below the industry median, indicating that top-line growth is relatively moderate within the industry.

※Source: Compiled by the Company

Key Points in the Earnings Results

1. Although the top line achieved revenue growth of 4.3%, the decline in gross margin and growth in selling, general and administrative expenses and research and development expenses (+16.4% and +22.9%, respectively) exceeded revenue growth, causing the Operating Income margin to decline to 9.6%. The impact of changes in the cost structure on earnings quality warrants close monitoring.

2. Inventories increased by ¥79.7B during the quarter, while OCF remained at -¥4.3B. A gap has emerged between earnings and cash generation, making inventory trends a structural issue affecting the quality of cash flow.

3. Progress against the full-year plan was 24.8% for Revenue, compared with 18.2% for Operating Income and 13.1% for Net Income, indicating a lag in earnings progress. The full-year plan anticipates significant earnings growth, making the presence or absence of a recovery in profitability toward the second half of the fiscal year an important point to monitor when evaluating actual performance.

Theoretical Share Price (Reference Value)

Sensitivity: 1,586 yen–1,679 yen at ±1% in the cost of equity, and 1,629 yen–1,635 yen at ±0.1 in ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / These are mechanically calculated values based solely on publicly disclosed data and do not constitute a forecast of the market share price or a recommendation of any specific investment action, nor do they predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---